MARKET

CELG-RT

CELG-RT

Celgene
NYSE

Real-time Quotes | Nasdaq Last Sale

0.3622
+0.0001
+0.03%
Closed 16:00 01/15 EST
OPEN
0.4000
PREV CLOSE
0.3621
HIGH
0.4000
LOW
0.3621
VOLUME
6.65K
TURNOVER
--
52 WEEK HIGH
0.7400
52 WEEK LOW
0.2551
MARKET CAP
257.67M
P/E (TTM)
0.0452
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Amgen second-quarter revenue rises 6%, shares fall 2%
Amgen Inc said on Tuesday second-quarter revenue rose 6% as higher sales of newer drugs, including recently added psoriasis treatment Otezla, offset declining sales of older medicines which were due in some cases to people staying home to avoid exposure to...
Reuters · 07/28/2020 22:37
US syndicated loan issuance tumbles as confidence drops
Trade wars, uncertainty about Brexit and a potential looming recession reduced US syndicated lending to US$2.11trn, an abysmal 20% drop from the prior record-year tally.
Reuters · 01/03/2020 17:57
Investment grade market was liquid, stable and muted in 2019
Issuance in the investment grade loan market was strong this year, though slightly down from 2018, supported by jumbo merger and acquisition (M&A) transactions, as the market proved its capacity to continue to fund big-ticket companies.
Reuters · 12/19/2019 17:26
$50M deal could expand NanoString Technologies diagnostic test into more markets
American City Business Journals · 12/03/2019 22:09
Tracking David Abrams' Abrams Capital Management Portfolio - Q3 2019 Update
Seeking Alpha - Article · 11/29/2019 15:26
Tracking John Paulson's Paulson & Company Portfolio - Q3 2019 Update
Seeking Alpha - Article · 11/29/2019 01:01
Merger Arbitrage Mondays - Novartis Confirms Acquisition Of The Medicines Company
Seeking Alpha - Article · 11/25/2019 12:13
Investing In The Holy Grail Of Cancer Treatment: Immunotherapy
Seeking Alpha - Article · 11/22/2019 18:34
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CELG-RT. Analyze the recent business situations of Celgene through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Institutional Holdings
Institutions: 24
Institutional Holdings: 605.20K
% Owned: 0.09%
Shares Outstanding: 711.40M
TypeInstitutionsShares
Increased
2
10.69K
New
1
90
Decreased
4
70.39K
Sold Out
1
14
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.43%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Chief Executive Officer/Director
Mark Alles
Executive Vice President
Peter Kellogg
Corporate Executive
Terrie Curran
Corporate Executive
Rupert Vessey
Corporate Executive
Michael Pehl
Executive Vice President/General Counsel
Jonathan Biller
Executive Vice President/General Counsel/Secretary
Gerald Masoudi
Chief Financial Officer/Executive Vice President
David Elkins
Lead Director
Michael Casey
Director
Hans Bishop
Director
Julia Haller
Independent Director
Richard Barker
Director
Patricia Hall
Independent Director
Michael Bonney
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 6.932592
10/08/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CELG-RT
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Celgene Corporation stock information, including NYSE:CELG RT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELG RT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CELG-RT stock methods without spending real money on the virtual paper trading platform.